Literature DB >> 6100598

Long-term clinical experience with enalapril in essential hypertension.

H R Brunner, B Waeber, J Nussberger, M D Schaller, H J Gomez.   

Abstract

This study was undertaken to evaluate whether, after long-term enalapril administration tachyphylaxis to the blockade of angiotensin II (Ang II) generation occurs. After a mean follow-up of 24 months, six patients taking enalapril once daily with or without an associated diuretic were studied for 7 h in hospital. Blood pressure, heart rate, plasma converting enzyme activity, angiotension I (Ang I), Ang II and aldosterone were measured before and 2, 4 and 6 h after the morning dose of enalapril. While blood pressure remained unchanged after drug administration, Ang II and aldosterone levels fell following enalapril to very low levels, similar to those observed during the initial study, at the time of peak effect of enalapril. After enalapril administration, there was no correlation between plasma Ang I and Ang II suggesting that blockade of Ang II generation was complete, excluding the possibility of Ang I related interference with the Ang II measurements. These results indicate that virtually complete angiotension converting enzyme inhibition can still be achieved after prolonged use of enalapril.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6100598

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  11 in total

1.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.

Authors:  S Ghiringhelli; E Cozzi; D Tsialtas
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

4.  The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.

Authors:  J P Bussien; J Nussberger; M Porchet; B Waeber; H R Brunner; M Perisic; M J Tansey; M Bomm; P Hajdu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

5.  Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.

Authors:  M D Schaller; J Nussberger; B Waeber; J P Bussien; G A Turini; H Brunner; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

7.  Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

Authors:  C I Johnston; B J Jackson; I Larmour; R Cubella; D Casley
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 8.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

9.  Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension.

Authors:  R A Sánchez; E Marcó; H B Gilbert; P Raffaele; M Brito; M Giménez; L I Moledo
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 10.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.